vs

Side-by-side financial comparison of ACNB CORP (ACNB) and Axogen, Inc. (AXGN). Click either name above to swap in a different company.

Axogen, Inc. is the larger business by last-quarter revenue ($61.5M vs $47.2M, roughly 1.3× ACNB CORP). ACNB CORP runs the higher net margin — 22.9% vs -31.9%, a 54.8% gap on every dollar of revenue. On growth, ACNB CORP posted the faster year-over-year revenue change (42.2% vs 26.6%). ACNB CORP produced more free cash flow last quarter ($52.6M vs $-1.4M). Over the past eight quarters, ACNB CORP's revenue compounded faster (22.1% CAGR vs 13.3%).

ACNB Corp is a US-based financial holding company headquartered in Pennsylvania. It provides a full suite of financial solutions including retail and commercial banking, wealth management, trust services, and property & casualty insurance products. Its core market covers local communities, individual consumers, and small-to-medium enterprises across south-central Pennsylvania and northern Maryland.

Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering (IPO). Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is...

ACNB vs AXGN — Head-to-Head

Bigger by revenue
AXGN
AXGN
1.3× larger
AXGN
$61.5M
$47.2M
ACNB
Growing faster (revenue YoY)
ACNB
ACNB
+15.6% gap
ACNB
42.2%
26.6%
AXGN
Higher net margin
ACNB
ACNB
54.8% more per $
ACNB
22.9%
-31.9%
AXGN
More free cash flow
ACNB
ACNB
$54.0M more FCF
ACNB
$52.6M
$-1.4M
AXGN
Faster 2-yr revenue CAGR
ACNB
ACNB
Annualised
ACNB
22.1%
13.3%
AXGN

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ACNB
ACNB
AXGN
AXGN
Revenue
$47.2M
$61.5M
Net Profit
$10.8M
$-19.6M
Gross Margin
75.2%
Operating Margin
27.9%
20.2%
Net Margin
22.9%
-31.9%
Revenue YoY
42.2%
26.6%
Net Profit YoY
63.8%
-410.8%
EPS (diluted)
$1.10
$-0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACNB
ACNB
AXGN
AXGN
Q1 26
$61.5M
Q4 25
$47.2M
$59.9M
Q3 25
$50.9M
$60.1M
Q2 25
$50.3M
$56.7M
Q1 25
$43.5M
$48.6M
Q4 24
$33.2M
$49.4M
Q3 24
$34.1M
$48.6M
Q2 24
$33.3M
$47.9M
Net Profit
ACNB
ACNB
AXGN
AXGN
Q1 26
$-19.6M
Q4 25
$10.8M
$-13.2M
Q3 25
$14.9M
$708.0K
Q2 25
$11.6M
$579.0K
Q1 25
$-272.0K
$-3.8M
Q4 24
$6.6M
$450.0K
Q3 24
$7.2M
$-1.9M
Q2 24
$11.3M
$-1.9M
Gross Margin
ACNB
ACNB
AXGN
AXGN
Q1 26
75.2%
Q4 25
74.1%
Q3 25
76.6%
Q2 25
74.2%
Q1 25
71.9%
Q4 24
76.1%
Q3 24
74.9%
Q2 24
73.8%
Operating Margin
ACNB
ACNB
AXGN
AXGN
Q1 26
20.2%
Q4 25
27.9%
-16.3%
Q3 25
37.2%
3.2%
Q2 25
29.7%
3.0%
Q1 25
-1.3%
-3.4%
Q4 24
24.8%
4.1%
Q3 24
27.6%
-0.6%
Q2 24
42.8%
-0.9%
Net Margin
ACNB
ACNB
AXGN
AXGN
Q1 26
-31.9%
Q4 25
22.9%
-22.0%
Q3 25
29.2%
1.2%
Q2 25
23.2%
1.0%
Q1 25
-0.6%
-7.9%
Q4 24
19.9%
0.9%
Q3 24
21.1%
-3.8%
Q2 24
33.9%
-4.0%
EPS (diluted)
ACNB
ACNB
AXGN
AXGN
Q1 26
$-0.38
Q4 25
$1.10
$-0.28
Q3 25
$1.42
$0.01
Q2 25
$1.11
$0.01
Q1 25
$-0.03
$-0.08
Q4 24
$0.77
$-0.00
Q3 24
$0.84
$-0.04
Q2 24
$1.32
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACNB
ACNB
AXGN
AXGN
Cash + ST InvestmentsLiquidity on hand
$65.6M
$82.7M
Total DebtLower is stronger
$255.4M
Stockholders' EquityBook value
$420.0M
$244.8M
Total Assets
$3.2B
$289.5M
Debt / EquityLower = less leverage
0.61×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACNB
ACNB
AXGN
AXGN
Q1 26
$82.7M
Q4 25
$65.6M
$41.5M
Q3 25
$102.1M
$35.8M
Q2 25
$103.1M
$29.9M
Q1 25
$123.6M
$22.1M
Q4 24
$47.3M
$33.5M
Q3 24
$58.1M
$24.5M
Q2 24
$86.3M
$21.1M
Total Debt
ACNB
ACNB
AXGN
AXGN
Q1 26
Q4 25
$255.4M
$48.4M
Q3 25
$255.4M
$48.2M
Q2 25
$255.4M
$47.9M
Q1 25
$255.3M
$47.7M
Q4 24
$255.3M
$47.5M
Q3 24
$255.3M
$47.3M
Q2 24
$255.3M
$47.0M
Stockholders' Equity
ACNB
ACNB
AXGN
AXGN
Q1 26
$244.8M
Q4 25
$420.0M
$128.8M
Q3 25
$408.6M
$120.8M
Q2 25
$395.2M
$112.3M
Q1 25
$386.9M
$105.4M
Q4 24
$303.3M
$103.9M
Q3 24
$306.8M
$99.4M
Q2 24
$289.3M
$95.7M
Total Assets
ACNB
ACNB
AXGN
AXGN
Q1 26
$289.5M
Q4 25
$3.2B
$221.7M
Q3 25
$3.3B
$216.4M
Q2 25
$3.3B
$205.5M
Q1 25
$3.3B
$196.2M
Q4 24
$2.4B
$203.7M
Q3 24
$2.4B
$192.0M
Q2 24
$2.5B
$188.9M
Debt / Equity
ACNB
ACNB
AXGN
AXGN
Q1 26
Q4 25
0.61×
0.38×
Q3 25
0.62×
0.40×
Q2 25
0.65×
0.43×
Q1 25
0.66×
0.45×
Q4 24
0.84×
0.46×
Q3 24
0.83×
0.48×
Q2 24
0.88×
0.49×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACNB
ACNB
AXGN
AXGN
Operating Cash FlowLast quarter
$53.6M
Free Cash FlowOCF − Capex
$52.6M
$-1.4M
FCF MarginFCF / Revenue
111.4%
-2.3%
Capex IntensityCapex / Revenue
2.3%
Cash ConversionOCF / Net Profit
4.96×
TTM Free Cash FlowTrailing 4 quarters
$92.2M
$9.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACNB
ACNB
AXGN
AXGN
Q1 26
Q4 25
$53.6M
$3.0M
Q3 25
$23.2M
$3.2M
Q2 25
$17.8M
$7.7M
Q1 25
$-71.0K
$-13.2M
Q4 24
$39.8M
$8.7M
Q3 24
$13.6M
$3.9M
Q2 24
$9.7M
$4.2M
Free Cash Flow
ACNB
ACNB
AXGN
AXGN
Q1 26
$-1.4M
Q4 25
$52.6M
$1.8M
Q3 25
$22.8M
$1.7M
Q2 25
$17.6M
$7.0M
Q1 25
$-730.0K
$-13.4M
Q4 24
$38.8M
$8.1M
Q3 24
$13.3M
$3.3M
Q2 24
$9.4M
$3.3M
FCF Margin
ACNB
ACNB
AXGN
AXGN
Q1 26
-2.3%
Q4 25
111.4%
3.0%
Q3 25
44.7%
2.8%
Q2 25
35.0%
12.4%
Q1 25
-1.7%
-27.7%
Q4 24
117.0%
16.3%
Q3 24
39.1%
6.8%
Q2 24
28.3%
6.8%
Capex Intensity
ACNB
ACNB
AXGN
AXGN
Q1 26
Q4 25
2.3%
2.1%
Q3 25
0.8%
2.5%
Q2 25
0.4%
1.3%
Q1 25
1.5%
0.5%
Q4 24
2.9%
1.4%
Q3 24
0.7%
1.2%
Q2 24
0.9%
1.9%
Cash Conversion
ACNB
ACNB
AXGN
AXGN
Q1 26
Q4 25
4.96×
Q3 25
1.56×
4.55×
Q2 25
1.52×
13.35×
Q1 25
Q4 24
6.03×
19.41×
Q3 24
1.88×
Q2 24
0.86×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons